| |
|
FULLSTORY
| |
| |
Anti-Angiogenesis Therapy For Metastatic Colorectal Cancer
|
| |
Groupe d'Étude en Oncologie du Québec webcast with Fairooz Kabbinavar MD
Fairooz Kabbinavar, Medical Oncologist, UCLA School of Medicine
Gerald Batist, Medical Oncologist, McGill University
Jean Maroun, Medical Oncologist, Ottawa Regional Cancer Centre
|
| |
Emergence of new drugs has dramatically improved the prognosis of metastatic colorectal cancer (mCRC) over the past twenty years. 5-fluorouracil (5-FU)/leucovorin plus oxaliplatin (FOLFOX) or irinotecan (IFL or FOLFIRI) are the most effective first-line chemotherapy regimens. Increased understanding of the biology of the disease have led to the development of targeted therapies such as bevacizumab (Avastin®). Bevacizumab is the only anti-angiogenic agent shown to improve survival outcomes in mCRC and has become the standard of care for first-line treatment with combination chemotherapy.
The learning objectives of the program include:
• Understanding the principles and rationale of anti-angioenic therapy in cancer
• Review pre-clinical studies evaluating the efficacy of anti-angiogenic therapy in cancer
• Discuss the current data and clinical applications with chemotherapy in mCRC and other tumours
• Discuss the safety profile of bevacizumab and other anti-angiogenic agents
• Application of learnings through case study discussion.
Click here to listen webcast archive
|
|
|
